Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab plus Nab-Paclitaxel and Carboplatin in Stage IV Squamous NSCLC
NCT02392507Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of necitumumab in squamous cell carcinoma of the lung (SCCL), sponsored by Eli Lilly and Company. Primary endpoint: Objective Tumor Response Rate up to 18 Months. Started Oct 2015; status: completed.
02
Drugs
necitumumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02392507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392507.